EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib, have been approved in 2004 by the US Food and Drug Administration for treating locally advanced or metastatic NSCLC [30].